Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07547878 · ClinicalTrials.gov registry record · Phase 4
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
A Phase 4 study, sponsored by Baylor Research Institute.
- Not yet
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT07547878: Clinical Trial Phase 4 study, sponsored by Baylor Research Institute.
NCT07547878 is a Phase 4 study that has not yet begun recruiting, run by Baylor Research Institute. The registered enrollment target is 64 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07547878, a Phase 4 study, has not yet begun recruiting, sponsored by Baylor Research Institute.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease. The main questions it aims to answer are: * Is it safe to start these medicines over a short period of time? * How often do kidney function changes or high potassium levels occur? * Does this approach lower protein in the urine (a sign of kidney damage)? * How many participants are able to stay on all four medicines over 6 months? Researchers will compare this approach to usual care, where medicines are started one at a time over several months. Participants will: Be assigned by chance to either this approach or usual care Start up to four approved kidney medicines over about 8 weeks (rapid treatment approach) or follow standard care Have regular clinic visits and lab tests to check kidney function and potassium levels Be followed for about 6 months
Primary Outcome
Proportion of participants who remain on all four guideline-directed CKD therapies at maximally tolerated doses without permanent discontinuation
Interventions
- DRUG Finerenone
- DRUG Semaglutide
- DRUG Enalapril
- DRUG Lotensin
- DRUG Capoten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 4 |
What is known before NCT07547878 opens enrollment
NCT07547878 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 5 interventions - of which Finerenone is the first listed.
NCT07547878 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07547878 about?
NCT07547878 is a clinical study titled "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)". The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease. The main questions it aims to answer are: * Is it safe to start these medicines ...
What is the current status of trial NCT07547878?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2026-04-30. Estimated completion is 2029-03-31.
What interventions are being tested in trial NCT07547878?
The interventions under investigation include: Finerenone (DRUG), Semaglutide (DRUG), Enalapril (DRUG), Lotensin (DRUG), Capoten (DRUG).
Who is sponsoring clinical trial NCT07547878?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07547878's enrollment target sits among peer trials
64 1098th of 2000 higher than 895 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI